Genocury Biotech Annouces Groundbreaking Advance in Relapsed/Refractory DLBCL Through Pioneering In Vivo CD19 CAR-T Therapy
Genocury launched the in vivo CD19 CAR-T therapy to reach the clinical stage, demonstrating exceptional safety, efficiency and durability.
Results are attained without requiring lymphodepletion.
SHENZHEN, China, April 30, 2025 /PR… อ่านเพิ่ม